Clinical trial · Observational
Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived Exosome
Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is linked to a better prognosis. Further, surgical resection at the early stages of non-small cell lung cancer (NSCLC) results in markedly improved survival rates. Computed tomography (CT)- or bronchoscopy-guided needle biopsies are standard definitive diagnostic procedures for lung cancer and are used to obtain tissue for pathological examination. However, these procedures are invasive, difficult to repeat, expensive, and risk exposure to radiation. Conversely, liquid biopsies, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), are simple and less invasive procedures that can be repeated more frequently than tissue biopsies. To analyze the exosomes abundantly present in the blood and to conduct clinical studies to determine whether it is possible to diagnose lung cancer. To this end, blood samples from normal people (n = 150) and lung cancer patients (n = 320) are obtained from the Human biobank of five hospitals participating in the study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exosome sampling | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Lung cancer
- interventionNames
- Diagnostic Test: Exosome sampling
- label
- Healthy
- interventionNames
- Diagnostic Test: Exosome sampling
Primary outcomes (2)
- measure
- Evaluation of the distinction between healthy controls and lung cancer patients through deep-learning analysis of exosomes
- timeFrame
- 3 years
- description
- Comparative evaluation of whether it is possible to distinguish between healthy controls and lung cancer patients through deep-learning analysis of exosomes
- measure
- Evaluating the possibility of distinguishing between normal and lung cancer patients through the analysis of lung cancer-specific exosomal protein
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with primary adenocarcinoma of lung with permanent pathology of N0 or N1 2. Patients with T1mi, Tsi, T1a, T1b, T1c, T2a, and T2b stage 3. An adult of Korean nationality 4. Patients without prior chemo/radiation treatment prior to lung cancer surgery 5. Patients who have not been diagnosed with other cancers prior to lung cancer surgery Exclusion Criteria: * Patients who do not meet the inclusion criteria
References
Publications (6)
- BACKGROUNDKaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 2006 Dec 1;66(23):11089-93. doi: 10.1158/0008-5472.CAN-06-2407. PMID 17145848
- BACKGROUNDPsaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009 Apr;9(4):285-93. doi: 10.1038/nrc2621. PMID 19308068
- BACKGROUNDTalmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010 Jul 15;70(14):5649-69. doi: 10.1158/0008-5472.CAN-10-1040. Epub 2010 Jul 7. PMID 20610625
- BACKGROUNDBidard FC, Pierga JY, Vincent-Salomon A, Poupon MF. A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev. 2008 Mar;27(1):5-10. doi: 10.1007/s10555-007-9103-x. PMID 18066649
- BACKGROUNDvan Akkooi AC, Verhoef C, Eggermont AM. Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. Nat Rev Clin Oncol. 2010 Aug;7(8):446-54. doi: 10.1038/nrclinonc.2010.100. Epub 2010 Jun 22. PMID 20567244
- DERIVEDChoi BH, An H, Cho S, Lee S, Kim HR, Cho JH, Lee JH, Kim GY, Jeon OH, Shin H, Choi Y, Kim HK. GCC2 in Small Extracellular Vesicles as a Diagnostic and Prognostic Biomarker of Early-Stage Lung Adenocarcinoma. J Extracell Vesicles. 2026 May;15(5):e70264. doi: 10.1002/jev2.70264. PMID 42087680